Health Canada
Santé Canada

STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: JTE 907

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled	☐
Not Controlled	X

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance is a cannabinoid receptor antagonist and is not captured under item 1 of Schedule II to the CDSA.

Prepared by: _____ Date: _____
Zack Li

Verified by: _____ Date: _____
Mark Kozlowski

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: "third party information removed as per agreement with applicant"

Drug Status Report

Drug: JTE 907

Drug Name Status: JTE 907 is the common name.

Chemical Name: N-(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide

Other Names: JTE-907

Chemical structure:



Molecular Formula: $C_{24}H_{26}N_2O_6$

Pharmacological class / Application: Synthetic cannabinoid

CAS-RN: 282089-49-0

International status:

US: JTE 907 is not listed specifically in the Schedules to the US *Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: JTE 907 is not listed in the schedules to the CDSA. The substance is a synthetic cannabinoid and in studies evaluating its anti-inflammatory effects, has been found to demonstrate CB_2 cannabinoid receptor antagonist activity[1]. Cannabinoid receptor agonists are currently included under the heading "Cannabis, its preparations, derivatives and similar synthetic preparations" of item 1 in Schedule II to the CDSA, whereas cannabinoid receptor antagonists are specifically excluded. Given that JTE 907 is a cannabinoid receptor antagonist, it cannot be included under item 1 of Schedule II to the CDSA.

[1]Iwamura. H et al. (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor, J Pharmacol Exp Ther. **296:** 420-425

Recommendation: JTE 907 is not included in the Schedules to the CDSA and is not a controlled substance.

Date: June 5th, 2012.